Roots Analysis Identifies 9 Leading Antibody Discovery Companies

Market research firm Roots Analysis has published a report highlighting nine key companies in the antibody discovery sector. The selections were based on the strength of companies' technology portfolios and recent initiatives aimed at providing efficient antibody drug discovery services.

The report underscores the growing importance of the antibody discovery market, driven by demand for antibody-based therapeutics. Many companies are increasingly outsourcing their antibody discovery processes to specialized contract manufacturing and development organizations (CMOs/CDMOs) that leverage innovative platforms to accelerate discovery workflows. Examples of this trend include companies like Myrio Therapeutics and Mabsilico, the latter utilizing computational approaches to streamline the process.

The antibody discovery market is projected for significant growth in the coming years. Roots Analysis forecasts a 12% compound annual growth rate (CAGR) from 2023 to 2035, fueled by demand for custom antibody services, including development and characterization. North America is expected to lead market expansion due to its advanced healthcare infrastructure and high R&D investment.

The report lists companies at the forefront of this field, including Ablexis, Creative Biolabs, Genmab, Harbour BioMed, Immunome, Isogenica, Kymab, Ligand Pharmaceuticals, and MorphoSys. These companies' contributions are crucial for the development of new antibody-based therapies, such as bispecific antibodies and antibody-drug conjugates (ADCs).